Lpath Sets Investor Update Conference Call for Thursday,

Lpath Sets Investor Update Conference Call for Thursday, January 3,
2013 at 4:30 p.m. ET 
SAN DIEGO, CA -- (Marketwire) -- 12/26/12 --   Lpath, Inc. (NASDAQ:
LPTN), the industry leader in bioactive lipid-targeted therapeutics,
will hold a conference call on Thursday, January 3, 2013 at 4:30 p.m.
Eastern time to provide an update on its Nexus Phase 2 trial for
iSONEP(TM), an ocular drug candidate, as well as outline the
company's 2013 objectives. 
Lpath President and CEO Scott Pancoast will host the presentation,
followed by a question-and-answer period. 
Date: Thursday, January 3, 2013
 Time: 4:30 p.m. Eastern time (1:30
p.m. Pacific time)
 Dial-in number: 1-877-941-1427
 International
dial-in: 1-480-629-9664
 Conference ID number: 4584568
 Webcast and
replay: http://public.viavid.com/index.php?id=102952 
Please call the conference telephone number 5-10 minutes prior to the
start time. If you have any difficulty connecting with the conference
call, please contact Liolios Group at 1-949-574-3860. 
A telephone replay of the call will be available after 7:30 p.m.
Eastern time on the same day and until February 3, 2013. 
Toll-free replay number: 1-877-870-5176
 International replay number:
1-858-384-5517
 Replay pin number: 4584568 
About Lpath
 San Diego-based Lpath, Inc., a therapeutic antibody
company, is the category leader in lipid-targeted therapeutics, an
emerging field of medicine that targets bioactive signaling lipids
for treating a wide range of human disease. Lpath's ImmuneY2(TM)
drug-discovery engine has the unique ability to generate therapeutic
antibodies that bind to and inhibit bioactive lipids that contribute
to disease. The company has developed three drug candidates:
iSONEP(TM) is currently in a Phase 2 trial for wet AMD; ASONEP(TM) is
scheduled to begin a Phase 2a trial in Renal Cell Carcinoma patients;
and Lpathomab is a preclinical drug candidate that holds promise in
neuropathic pain, neurotrauma, and other diseases. For more
information, visit www.Lpath.com. 
Lpath, Inc.
Scott R. Pancoast
President & CEO
(858) 926-3200
spancoast@Lpath.com  
Lpath Investor Relations
Liolios Group, Inc. 
(949) 574-3860
Ron Both: ron@liolios.com 
Geoffrey Plank: geoffrey@liolios.com
LPTN@liolios.com 
 
 
Press spacebar to pause and continue. Press esc to stop.